Searle/Invitron ADBF agreement
Executive Summary
Terminated Aug. 13. All rights to develop and commercialize azurophil derived bactericidal factor, a white blood cell-derived protein with antimicrobial activity, were reconveyed to Invitron. Searle parent Monsanto has a controlling interest in Invitron. The St. Louis-based biotech firm recently announced the isolation of another protein from human white blood cells, called granulocidin, which may have broad spectrum antibacterial and antifungal activity